Role of telomere length in assessing prognosis of pneumonias severity of different etiology: open prospective non-intervention study

Cover Page

Cite item

Full Text

Abstract

INTRODUCTION: Searching for an early marker in assessing the severity of community-acquired pneumonia is a global issue in modern medicine. As such a biological marker of community-acquired pneumonia severity, the assessment of telomere length peripheral blood lymphocytes on the day of inpatient treatment may be suggested.
OBJECTIVE: Study prognostic value of telomere length in assessing prognosis of pneumonia severity of different etiology.
MATERIALS AND METHODS: The study involved a group of 97 patients with community-acquired pneumonia of different etiology (viral pneumonia, caused by COVID-19 and bacterial pneumonias). Blood samples were taken on admission and discharge from hospital in accordance with informed voluntary consent. Telomeres were measured in DNA, secreted from peripheral blood lymphocytes, using the manufacturer’s protocol kit (Biolabmix, Novosibirsk).
RESULTS: Depending on the severity, the assessment of telomere length in patients with viral pneumonias showed that in the group 1 at admission the value of this indicator was 6343 (6114; 6422) kilobases, whereas in the second group it was statistically significantly lower - 5264 (5057; 5423) kilobases (p<0.001).
DISCUSSION: The study results showed that all patients with severe viral pneumonia, caused by a new coronavirus infection, after 3 weeks in hospital experienced significant reduction of telomere length not less than 2000 base pairs. Analyzing the data, we managed to confirm the hypothesis of much more severe viral pneumonia in patients with low telomere lengths. CONCLUSION: It was found that telomere length changes significantly in the dynamics of bacterial and viral pneumonia and can be considered as a marker of severity and prognosis of the disease course in the early stages of diagnosis.

About the authors

R. G. Makiev

Military Medical Academy named after S.M. Kirov

Email: moro5555@yandex.ru
ORCID iD: 0000-0002-2180-6885
SPIN-code: 4703-5573

Ruslan G. Makiev – Dr. of Sci. (Med.), Associate  Professor, Colonel of the medical service, Deputy Head

194044, Saint Petersburg, Academician Lebedev str., 6

Russian Federation

I. V. Mironov

Military Medical Academy named after S.M. Kirov

Author for correspondence.
Email: ilyamirono@mail.ru
ORCID iD: 0000-0001-8382-8951
SPIN-code: 9427-5456

Ilya V. Mironov – Adjunct of the Department of  Hospital Therapy

194044, Saint Petersburg, Academician Lebedev str., 6

Russian Federation

References

  1. Shoar S., Musher D.M. Etiology of community-acquired pneumonia in adults: a systematic review. Pneumonia, 2020, Vol. 12, № 1, pp. 1–10.
  2. Hespanhol V., Barbara С. Pneumonia mortality, comorbidities matter? Pulmonology, 2020, Vol. 26, № 3, pp. 123–129.
  3. Bjarnason A. Incidence, etiology, and outcomes of community-acquired pneumonia: a population-based study. Open forum infectious diseases. US: Oxford University Press, 2018, Vol. 5, № 2, pp. 1–9.
  4. Ярощук Н. А., Кочмашева В. В., Вахрамеев А. В. Кардиологические осложнения у пациентов с тяжелым течением пневмонии COVID-19 // Медицинский алфавит. 2021. № 5. C. 14–17
  5. Sandoval Y., Januzzi Jr J. L., Jaffe A.S. Cardiac troponin for the diagnosis and risk-stratification of myocardial injury in COVID‑19: JACC review topic of the week. Journal of the American College of Сardiology, 2020, № 76, № 10, pp. 1244–1258.
  6. Guo T. Fan Y., Chen M., Wu X., Zhang L., He T., Lu Z. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID‑19). Journal of the American College of Сardiology, 2020, Vol. 7, № 5, pp. 811–818.
  7. Violi F. Cardiovascular Complications and Short-term Mortality: Risk in Community-Acquired Pneumonia. Clinical Infectious Diseases, 2017, Vol. 64, № 11, pp. 1486–1493.
  8. Tang N., Bai H., Chen X., Gong J., Li D., Sun Z.J. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of thrombosis and haemostasis. 2020, Vol. 18, № 5, pp. 1094–1099.
  9. Хавинсон В.Х., Кузник Б.И. Осложнения у больных CОVID-19. Предполагаемые механизмы коррекции // Клиническая медицина. 2020. Т. 98, № 4. С. 256–265
  10. Huang I., Lim M.A., Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020, № 14, pp. 395–403.
  11. Ramirez J.A., et al. Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality. Clinical Infectious Deseases, 2017, Vol. 65, № 11, pp. 1806–1812.
  12. Giesen C. Epidemiological characteristics of the COVID-19 outbreak in a secondary hospital in Spain. American Journal of Infection Control, 2021, Vol. 49, № 2, pp. 143–150.
  13. Arnold F.W. A Worldwide Perspective of Atypical Pathogens in Community-acquired Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2007, Vol. 175, № 10, P.1086–1093.
  14. Миронов И.В., Спивак И.М. Совершенствование лабораторной диагностики пневмоний различной этиологии // Известия Российской Военно-медицинской академии. 2021. Т. 40, № S1. С. 96–98
  15. Спивак И.М., Жекалов А.Н., Миронов И.В., Глушаков Р.И. Длина теломер как возможный предиктор тяжести протекания пневмонии, вызванной COVID-19 // Известия Российской Военно-медицинской академии. 2020. Т. 39, № S3-1. С. 205–209
  16. Cпивак И.М., Жекалов А.Н., Миронов И.В., Слижов П.А., Глушаков Р.И. Укорочение длины теломер при пневмонии, вызванной новой коронавирусной инфекцией // Здоровье – основа человеческого потенциала: проблемы и пути их решения. 2021. Т. 16, № 1. С. 371–377
  17. Миронов И.В., Гордиенко А.В., Сердюков Д.Ю., Чумак Б.А., Яковлев В.В. Длина теломер, тяжесть течения коронавирусной инфекции и преждевременное старение (обзор литературы) // Медико-фармацевтический журнал «Пульс». 2022. Т. 24, № 4. С. 84–89 doi: 10.26787/nydha-2686-6838-2022-24-4-84-89
  18. Миронов И.В., Гордиенко А.В., Чумак Б.А., Львов Н.И. Длина теломер как биологический маркер оценки тяжести течения пневмоний различной этиологии // Медико-фармацевтический журнал «Пульс». 2022. Т. 24, № 5. С. 114–121. doi: 10.26787/nydha-2686-6838-2022-24-5-114-121.
  19. Миронов И.В., Гордиенко А.В., Чумак Б.А., Львов Н.И. Изучение влияния длины теломер на клиническую картину пневмоний различной этиологии // Медико-фармацевтический журнал «Пульс». 2022. Т. 24, № 10. С. 64–71. doi: 10.26787/nydha-2686-6838-2022-24-10-64-71.
  20. Временные методические рекомендации: профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 11 (07.05.2021). М., 2021. 225 с.
  21. Cawthon R.M. Telomere measurement by quantitative PCR. Nucleic Acids Research. 2002. Vol. 30, Iss. 10, pp. e47.
  22. O’Callaghan N.J., Dhillon V.S., Thomas P., Fenech M. A quantitative real-time PCR method for absolute telomere length. Biotechniques. 2008, № 44, pp. 807–819. doi: 10.1093/nar/30.10.e4725.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Makiev R.G., Mironov I.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies